6-K

LEGEND BIOTECH CORPORATION

(Registrant)

May 20, 2021

/s/ Ying Huang

Ying Huang, Ph.D.

Chief Executive Officer and Chief Financial Officer

0001193125-21-167603.txt : 20210520 0001193125-21-167603.hdr.sgml : 20210520 20210520140628 ACCESSION NUMBER: 0001193125-21-167603 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210520 FILED AS OF DATE: 20210520 DATE AS OF CHANGE: 20210520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Legend Biotech Corp CENTRAL INDEX KEY: 0001801198 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39307 FILM NUMBER: 21943845 BUSINESS ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 732-317-5050 MAIL ADDRESS: STREET 1: 2101 COTTONTAIL LANE CITY: SOMERSET STATE: NJ ZIP: 08873 6-K 1 d143280d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: May 20, 2021

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Legend Biotech Corporation Announces EMA Acceptance of the MAA for Cilta-Cel for RRMM

Legend Biotech Corporation (“Legend Biotech”) announces that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) seeking approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM). The acceptance of the MAA confirms that the application is valid and marks the commencement of the EMA’s assessment process. Pursuant to Legend Biotech’s collaboration agreement with Janssen Biotech, Inc., Legend Biotech will receive a milestone payment of U.S.$15 million relating to the EMA’s acceptance of the MAA.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.